SEC Form DEF 14A filed by Sight Sciences Inc.

Check the appropriate box:

Payment of Filing Fee (Check all boxes that apply):

 

NOTICE & PROXY STATEMENT

 

2026 Annual Meeting of Stockholders

Thursday, June 4, 2026

9:00 a.m. Pacific Time

 

April 22, 2026

To Our Stockholders:

You are cordially invited to attend the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Sight Sciences, Inc. at 9:00 a.m. Pacific Time, on Thursday, June 4, 2026. The Annual Meeting will be held virtually via live webcast at www.virtualshareholdermeeting.com/SGHT2026.

The Notice of Virtual Annual Meeting of Stockholders and Proxy Statement on the following pages describe the matters to be presented at the Annual Meeting. Please see the section of the Proxy Statement titled “Who may attend the Annual Meeting?” for more information about how to attend the Annual Meeting online.

Whether or not you plan to attend the Annual Meeting, it is important that your shares be represented and voted at the Annual Meeting. We encourage you to read the Proxy Statement and promptly submit your proxy or voting instructions as soon as possible. For specific instructions on how to vote your shares, please refer to the instructions on the Notice of Internet Availability of Proxy Materials you received in the mail, the section of the Proxy Statement titled “Questions and Answers About the 2026 Annual Meeting of Stockholders,” or, if you requested to receive printed proxy materials, your printed proxy card. If you decide to attend the Annual Meeting, you will be able to vote online, even if you have previously submitted your proxy.

Thank you for your support.

 

To Our Stockholders:

We are pleased to invite you to virtually attend the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Sight Sciences, Inc., a Delaware corporation (the “Company,” “our,” or “us”), which will be held at 9:00 a.m. Pacific Time on Thursday, June 4, 2026. The Annual Meeting will be held virtually via live webcast. You will be able to attend the Annual Meeting online, submit your questions and vote your shares during the meeting by visiting www.virtualshareholdermeeting.com/SGHT2026 and entering your 16-digit control number included on your Notice of Internet Availability of Proxy Materials, on your proxy card, or on the instructions that accompanied your proxy materials. The Annual Meeting will be held for the following purposes:

Holders of record of our common stock as of the close of business on April 8, 2026 are entitled to notice of and to vote at the Annual Meeting, or any continuation, postponement or adjournment of the Annual Meeting. A complete list of such stockholders will be open to the examination of any stockholder for any purpose germane to the Annual Meeting for a period of ten days prior to the Annual Meeting and may be requested by sending an email to Jeremy Hayden, Chief Legal Officer, at [email protected], stating the purpose of the request and providing proof of ownership of our common stock. The list of these stockholders will also be available on your screen during the Annual Meeting after entering the 16-digit control number included on your Notice of Internet Availability of Proxy Materials, on your proxy card, or on the instructions that accompanied your proxy materials. The Annual Meeting may be continued, postponed or adjourned from time to time without notice other than by announcement at the Annual Meeting.

It is important that your shares be represented at the Annual Meeting regardless of the number of shares you may hold. Whether or not you plan to attend the virtual Annual Meeting, we encourage you to read this Proxy Statement and submit your proxy or voting instructions as soon as possible to ensure your representation at the Annual Meeting. Please refer to the section of this Proxy Statement titled “Questions and Answers About the 2026 Annual Meeting of Stockholders” for additional information on how to attend the Annual Meeting and vote your shares. If you received a copy of the proxy card by mail, you may sign, date and mail the proxy card in the enclosed return envelope. Promptly voting your shares will ensure the presence of a quorum at the Annual Meeting and will save us the expense of further proxy solicitation. Submitting your proxy now will not prevent you from voting your shares at the Annual Meeting if you desire to do so, as your proxy is revocable at your option.

Menlo Park, California

April 22, 2026

Approximate Date of Mailing of Notice of Internet Availability of Proxy Materials: April 22, 2026

This Proxy Statement contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may relate to our future financial performance, results of operations, business outcomes, governance decisions, executive compensation, or other future events. You can identify forward-looking statements by the use of words such as “may,” “will,” “could,” “anticipate,” “expect,” “intend,” “believe,” “continue,” or the negative of such terms, or other comparable terminology. Forward-looking statements also include the assumptions underlying or relating to such statements. We have based these forward-looking statements on our current expectations and projections about future events that we believe may affect our business, results of operations and financial condition.

The outcomes of the events described in these forward-looking statements are subject to risks, uncertainties and other factors described in Item 1A, “Risk Factors,” and elsewhere, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “2025 Annual Report”), as well as the other reports we file with the Securities and Exchange Commission (the “SEC”) from time to time. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those expressed in or implied by the forward-looking statements. The forward-looking statements made in this Proxy Statement relate only to events as of the date of this Proxy Statement. We undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made.

 

This Proxy Statement is furnished in connection with the solicitation by the Board of Directors (the “Board”) of Sight Sciences, Inc. of proxies to be voted at our Annual Meeting of Stockholders to be held at 9:00 a.m. Pacific Time, on Thursday, June 4, 2026 (the “Annual Meeting”), and at any continuation, postponement or adjournment of the Annual Meeting. The Annual Meeting will be a completely virtual meeting, which will be conducted via live webcast. You will be able to attend the Annual Meeting online, submit your questions and vote your shares during the meeting by visiting www.virtualshareholdermeeting.com/SGHT2026 and entering your 16-digit control number included on your Notice of Internet Availability of Proxy Materials, on your proxy card, or on the instructions that accompanied your proxy materials.

Holders of record of our common stock as of the close of business on April 8, 2026 (the “Record Date”) will be entitled to notice of and to vote at the Annual Meeting, and at any continuation, postponement or adjournment of the Annual Meeting, and will vote together as a single class on all matters presented at the meeting. Each share of our common stock entitles its holder to one vote per share on each matter presented to our stockholders. As of the Record Date, there were 54,403,542 shares of common stock outstanding and entitled to vote at the Annual Meeting.

This Proxy Statement and the 2025 Annual Report will be made available on or about April 22, 2026 to our stockholders on the Record Date.

In this Proxy Statement, “Sight,” “Sight Sciences,” “Company,” “we,” “us,” and “our” refer to Sight Sciences, Inc.

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE

ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON THURSDAY, JUNE 4, 2026

This Proxy Statement and the 2025 Annual Report are available at http://www.proxyvote.com

At the Annual Meeting, our stockholders will be asked:

We are not aware of any other business that will be presented for consideration at the Annual Meeting other than the matters described herein and do not currently intend to bring any other matters before the Annual Meeting. However, if other matters are properly presented at the Annual Meeting, the persons named as proxies on the Company’s proxy card will vote your shares in accordance with their discretion with respect to those matters.

The Board recommends that you vote your shares as indicated below. If you vote your shares by telephone or Internet, or return a properly completed proxy card, your shares will be voted on your behalf as you direct. If not otherwise specified, the shares represented by the proxies will be voted, and the Board recommends that you vote:

If any other business is presented to our stockholders at the Annual Meeting, the proxies named on the Company’s proxy card will vote thereon in their discretion. The Board is not aware of any matters to be presented for consideration at the Annual Meeting other than the matters described herein and does not currently intend to bring any other matters before the Annual Meeting.

Why You Received this Proxy Statement. You are viewing or have received these proxy materials because our Board is soliciting your proxy to vote your shares at the Annual Meeting. This Proxy Statement includes information that we are required to provide to you under the rules of the SEC and that is designed to assist you in voting your shares.

Notice of Internet Availability of Proxy Materials. As permitted by SEC rules, Sight Sciences is making this Proxy Statement and the 2025 Annual Report available to its stockholders electronically via the Internet. On or about April 22, 2026, we mailed to our stockholders a Notice of Internet Availability of Proxy Materials (the “Internet Notice”) containing instructions on how to access this Proxy Statement and the 2025 Annual Report and vote their shares. If you received an Internet Notice by mail, you will not receive a printed copy of the proxy materials in the mail unless you specifically request them. Instead, the Internet Notice instructs you on how to access and review all of the important information contained in this Proxy Statement and the 2025 Annual Report. The Internet Notice also instructs you on how you may submit your proxy. If you received an Internet Notice by mail and would like to receive a printed copy of our proxy materials, you should follow the instructions for requesting such materials contained on the Internet Notice.

Printed Copies of Our Proxy Materials. If you received printed copies of our proxy materials, then instructions regarding how you can vote are contained on the proxy card included in the materials.

Householding. The SEC’s rules permit us to deliver a single set of proxy materials to one address shared by two or more of our stockholders. This delivery method is referred to as “householding” and can result in significant cost savings. To take advantage of this opportunity, we have delivered only one set of proxy materials to multiple stockholders who share an address, unless we received contrary instructions from the impacted stockholders prior to the mailing date. We agree to deliver promptly, upon written or oral request, a separate copy of the proxy materials, as requested, to any stockholder at the shared address to which a single copy of those documents was delivered. If you prefer to receive separate copies of the proxy materials, contact Broadridge Financial Solutions, Inc. (“Broadridge”) by telephone at 1-866-540-7095 or in writing at Broadridge, Householding Department, 51 Mercedes Way, Edgewood, New York 11717. If you are currently a stockholder sharing an address with another stockholder and wish to receive only one copy of future proxy materials for your household, please contact Broadridge at the above telephone number or address.

We believe hosting a virtual annual meeting encourages increased stockholder attendance and participation because stockholders can participate from any location around the world. A virtual meeting format also reduces the costs to the Company associated with holding the Annual Meeting, as well as the cost to our stockholders of attending the meeting. You will be able to attend the Annual Meeting online, submit your questions and vote your shares during the meeting by visiting http://www.virtualshareholdermeeting.com/SGHT2026.

You may attend and participate in the virtual Annual Meeting only if you are a Sight Sciences stockholder of record as of the close of business on the Record Date, or if you hold a valid proxy for the Annual Meeting. You may attend and participate in the Annual Meeting by visiting the following website: www.virtualshareholdermeeting.com/SGHT2026. To attend and participate in the Annual Meeting, you will need the 16-digit control number included on your Internet Notice, on your proxy card, or on the instructions that accompanied your proxy materials. If your shares are held in “street name,” you should contact your bank or brokerage firm to obtain your 16-digit control number or to otherwise obtain instructions to vote your shares through your bank or brokerage firm. If you lose your 16-digit control number, you may join the Annual Meeting as a “Guest”, but you will not be able to vote, ask questions or access the list of stockholders as of the Record Date.

The Annual Meeting webcast will begin promptly at 9:00 a.m. Pacific Time. We encourage you to access the Annual Meeting prior to the start time. Online check-in will begin at 8:45 a.m. Pacific Time, and you should allow ample time for the check-in procedures.

A quorum must be present at the Annual Meeting for any business to be conducted. The presence at the Annual Meeting online or by proxy of the holders of a majority of the voting power of all of the shares of our common stock issued and outstanding and entitled to vote as of the close of business on the Record Date will constitute a quorum. If a quorum is not present, the Annual Meeting will be adjourned until a quorum is obtained.

The Record Date for the Annual Meeting is April 8, 2026. You are entitled to vote at the Annual Meeting only if you were a “record holder” at the close of business on that date, or if you hold a valid proxy for the Annual Meeting. Each outstanding share of our common stock is entitled to one vote for each matter before the Annual Meeting. At the close of business on the Record Date, there were 54,403,542 shares of common stock outstanding and entitled to vote at the Annual Meeting.

A record holder holds shares in his or her name with our transfer agent. As a record holder, you may vote at the Annual Meeting or by proxy. If you are a record holder and you indicate when voting that you wish to vote as recommended by our Board, or if you submit a vote by proxy without giving specific voting instructions, then the proxies named on the Company’s proxy card will vote your shares as recommended by our Board on all matters described in this Proxy Statement. Paul Badawi and James Rodberg, the designated proxies, are members of our management.

If, on the Record Date, your shares were held in an account at a bank or brokerage firm, then you are the “beneficial owner” of those shares held in “street name” and these proxy materials are being provided to you by your bank or brokerage firm, along with a voting instruction card if you received printed copies of the proxy materials. The nominee holding your account is considered the record holder for purposes of voting at the Annual Meeting. As the beneficial owner, you have the right to direct your bank or brokerage firm how to vote your shares, and the bank or brokerage firm is required to vote your shares in accordance with your instructions. If your shares are held in street name, you may not vote your shares online at the Annual Meeting unless you obtain a legal proxy from your bank or brokerage firm.

Generally, broker non-votes occur when shares held in “street name” for a beneficial owner are not voted with respect to a particular proposal because the broker (i) has not received voting instructions from the beneficial owner, and (ii) lacks discretionary voting power to vote those shares. A broker is entitled to vote shares held for a beneficial owner

on routine matters, such as Proposal 2, without instructions from the beneficial owner of those shares. On the other hand, absent instructions from the beneficial owner of such shares, a broker is not entitled to vote shares held for a beneficial owner on non-routine matters, such as Proposal 1. Broker non-votes count for purposes of determining whether a quorum is present.

Record Holders. If you are a record holder, you may vote:

Internet and telephone voting facilities for stockholders of record will be available 24 hours a day and will close at 11:59 p.m., Eastern Time, on Wednesday, June 3, 2026. To participate in the Annual Meeting, including to vote via the Internet or telephone, you will need the 16-digit control number included on your Internet Notice, on your proxy card, or on the instructions that accompanied your proxy materials.

Whether or not you expect to attend the Annual Meeting online, we urge you to vote your shares as promptly as possible to ensure your representation and the presence of a quorum at the Annual Meeting. If you submit your proxy, you may still decide to attend the Annual Meeting and vote your shares electronically.

Beneficial Owners of Shares Held in “Street Name.” If your shares are held in “street name” through a bank or brokerage firm, you will receive instructions on how to vote from the bank or brokerage firm. You must follow their instructions in order for your shares to be voted. Internet and telephone voting may be offered to stockholders owning shares through certain banks and brokers. If your shares are not registered in your own name and you would like to vote your shares online at the Annual Meeting, you should contact your bank or brokerage firm to obtain a 16-digit control number or to otherwise obtain instructions to vote your shares through your bank or brokerage firm. If you lose your 16-digit control number, you may join the Annual Meeting as a “Guest”, but you will not be able to vote, ask questions or access the list of stockholders as of the Record Date.

It means that your shares are held in more than one account at the transfer agent and/or with banks or brokers. Please vote all of your shares held in each account. To ensure all of your shares are voted, for each Internet Notice or set of proxy materials, please submit your proxy by telephone or over the Internet, or, if you received printed copies of the proxy materials, by signing, dating and returning the proxy card in the enclosed envelope.

Yes. If you are a record holder, you may revoke your proxy and change your vote:

Your most recent proxy card or Internet or telephone proxy is the one that is counted. Your attendance at the Annual Meeting by itself will not revoke your proxy unless you give written notice of revocation to the Corporate Secretary before your proxy is voted or you vote online at the Annual Meeting.

If you are a beneficial owner of shares held in street name, you may change or revoke your voting instructions by following the directions provided to you by your bank or brokerage firm, or you may vote online at the Annual Meeting by obtaining your 16-digit control number or otherwise voting through the bank or brokerage firm.

A representative of Broadridge, our inspector of election, will tabulate and certify the votes.

If you submit a proxy but do not provide any voting instructions, the persons named as proxies on the Company’s proxy card will vote in accordance with the recommendations of the Board. The Board’s recommendations are described above.

We will have technicians ready to assist you with any technical difficulties you may have accessing the virtual meeting website, and the information for assistance will be located on www.virtualshareholdermeeting.com/SGHT2026.

As part of the Annual Meeting, we will hold a live question and answer session, during which we intend to answer questions submitted online during the meeting that are pertinent to the business of the Annual Meeting, as time permits. Only stockholders that have accessed the Annual Meeting as a stockholder (rather than as a “Guest”) by following the procedures discussed above will be permitted to submit questions during the Annual Meeting. Each stockholder is limited to no more than two questions. Questions should be succinct and only cover a single topic.

We will not address questions that are, among other things:

Additional information regarding the question and answer session will be available in the “Rules of Conduct” available on the Annual Meeting webpage for stockholders that have accessed the Annual Meeting as a stockholder.

We plan to announce preliminary voting results at the Annual Meeting. We will report the final results in a Current Report on Form 8-K, which we intend to file with the SEC within four business days after the Annual Meeting, unless final results are not known at that time, in which case preliminary voting results will be reported within four business days of the Annual Meeting, and final voting results will be reported once we know them.

At the Annual Meeting, our stockholders are being asked to vote for two Class II Director nominees, Gerhard Burbach and Staffan Encrantz, to hold office until the 2029 Annual Meeting of Stockholders and until each such director’s respective successor is elected and qualified, or until each such director’s earlier death, resignation or removal. Each of the director nominees is a current member of the Board and a Class II Director whose term expires at the Annual Meeting.

Each director nominee has consented to serve if elected, and the Board has no reason to believe that any of the nominees will be unable or unwilling to serve as a director. If, however, either of Gerhard Burbach or Staffan Encrantz withdraws or otherwise becomes unable to serve, our Board may decrease the size of the Board, or the proxies may be voted for the election of a substitute director nominee our Board may recommend in place of the nominee.

We currently have seven directors on our Board. Our Restated Certificate of Incorporation and Amended and Restated Bylaws provide that the authorized number of directors may be changed from time to time by the Board.

As set forth in our Restated Certificate of Incorporation, the Board is currently divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. The current class structure of the Board is as follows: Class I Directors, whose term will expire at the 2028 Annual Meeting of Stockholders, Class II Directors, whose current term will expire at the Annual Meeting and if elected at the Annual Meeting, whose subsequent term will expire at the 2029 Annual Meeting of Stockholders, and Class III Directors whose term will expire at the 2027 Annual Meeting of Stockholders. The current Class I Directors are Paul Badawi and Catherine Mazzacco; the current Class II Directors are Gerhard Burbach and Staffan Encrantz; and the current Class III Directors are David Badawi, M.D., Tamara Fountain, M.D. and Donald Zurbay.

Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. Our directors may be removed only for cause by the affirmative vote of the holders of at least two-thirds of the voting power of all of the then outstanding shares of voting stock of the Company entitled to vote at an election of directors.

The proposal regarding the election of directors requires the approval of a plurality of the votes cast. This means that the two nominees receiving the highest number of affirmative “FOR” votes will be elected as Class II Directors. Votes withheld and broker non-votes are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal.

The nominees for election to the Board as Class II Directors are as follows:

Staffan Encrantz has served as Chairperson of the Board since October 2017. Mr. Encrantz is the President and Founder of Allegro Investment Inc., the investment manager of Allegro Investment Fund, L.P., and has served as such since 1997. He has over 30 years of experience in the management and operations of companies in an array of industries and in a variety of roles, including as an executive, board member and investor. Mr. Encrantz serves on the boards of directors of various private operating entities across a range of industries, including service as chairperson on a number of these boards. Mr. Encrantz holds a Bachelor of Law and a Business Studies degree from Uppsala University, Sweden.

We believe Mr. Encrantz’ financial and industry experience and wealth of board experience, including service as chairperson of a number of commercial operating entities within and outside of the life sciences industry, qualify him to serve on our Board.

Mr. Burbach has served as a member of our Board since April 2025. Mr. Burbach is a member of the Board of Directors and Chair of the Compensation Committee of BWX Technologies (NYSE: BWXT), a publicly traded company that provides innovative nuclear technology solutions in numerous markets including power and medicine, Chairman of the Board of Directors of Procyrion Inc., a private medical device company focused on the interventional treatment of chronic heart failure, and Chairman of the Board of Directors of Rampart IC, Inc., a private medical technology company providing solutions for interventional medicine radiation safety. He has also served as a member of the board of directors of several other medical technology companies, including most recently Artelon, Fluidigm Corporation, and Brius Technologies. From 2006 to 2014, Mr. Burbach was the President, Chief Executive Officer and a member of the Board of Directors of Thoratec Corporation, a manufacturer of proprietary medical devices for circulatory support that was acquired by St. Jude Medical, Inc. (now Abbott Laboratories (NYSE: ABT)). Prior to that, he held executive leadership positions at Digirad Corporation, Philips Medical Systems, and ADAC Laboratories. Mr. Burbach also spent six years at McKinsey & Company, Inc., focused primarily on the firm’s healthcare practice. Mr. Burbach holds a B.S. in Industrial Engineering from Stanford University and an M.B.A from Harvard Business School.

We believe Mr. Burbach’s extensive experience in the medical device industry, and his tenures as a senior executive officer and director of multiple publicly traded companies, qualifies him to serve on our Board.

The current members of the Board who are Class I Directors are as follows:

The principal occupations and business experience, for at least the past five years, of each Class I Director are as follows:

Paul Badawi is a co-founder of our Company and has served as our President, Chief Executive Officer and a member of our Board since the Company was founded in 2011. Prior to launching the Company, Mr. Badawi led the

U.S. healthcare venture capital practice of 3i Group plc, a global private equity firm. Prior to 3i, Mr. Badawi worked at the National Institutes of Health as a Research Fellow in the field of biochemical genetics. Mr. Badawi holds an M.B.A. from the University of California, Los Angeles and a B.S. in Biological Sciences from the University of Chicago.

We believe Mr. Badawi’s extensive experience in the industry and knowledge of our Company qualify him to serve on our Board.

Catherine Mazzacco has served as a member of our Board since June 2023. Ms. Mazzacco was Chief Executive Officer and President of LEO Pharma, a privately owned global pharmaceutical company, and a member of its board of directors, from August 2019 to November 2021. Prior to this role, Ms. Mazzacco was Senior Vice President, Global Commercial Operations, Life Sciences Division at GE HealthCare Technologies, Inc. (Nasdaq: GEHC) (“GE HealthCare”), a leading publicly traded global medical technology company, from February 2018 to May 2019. Before joining GE HealthCare, Ms. Mazzacco spent over 25 years at Abbott Laboratories (NYSE: ABT), a multinational publicly traded healthcare company where she held several global senior operational and strategic leadership roles, including, most recently, as Vice President, Global Commercial Operations, Abbott Vision Division from 2011 to 2017. Ms. Mazzacco has served as a member of the board of directors and a member of the nominating and governance committee and commercial advisory committee of Krystal Biotech, Inc. (Nasdaq: KRYS), a publicly traded gene therapy biotechnology company, since March 2023. Ms. Mazzacco has served as a member of the supervisory board and remuneration and nomination committee of Servier SAS, a privately owned global pharmaceutical company, since February 2022. Ms. Mazzacco holds a B.S. in Engineering, Option Biotechnology from the University of Compiègne in France.

We believe Ms. Mazzacco’s deep healthcare knowledge as well as her extensive international, commercial, financial, operational and transformation expertise qualifies her to serve on our Board.

The current members of the Board who are Class III Directors are as follows:

David Badawi is a co-founder of our Company and has served as our Chief Technology Officer and a member of our Board since the Company was founded in 2011. Since 2012, Dr. Badawi has also served as the president and a practicing ophthalmologist at Central Eye Care Ltd, an ophthalmology practice. Dr. Badawi holds an M.D. from Georgetown University and a B.S. in Microbiology from the University of Maryland. He completed his residency in ophthalmology at the Jules Stein Eye Institute at the University of California, Los Angeles and a cornea fellowship at Emory University.

We believe that Dr. Badawi’s ophthalmic medical experience and extensive knowledge of our Company and industry qualify him to serve on our Board.

Tamara Fountain, M.D. has served as a member of our Board since July 2022. She has also served as a member of the board of directors and a member of the audit committee of RxSight, Inc. (Nasdaq: RXST), a medical device manufacturer, since January 2022. Since 2025, Dr. Fountain has served as the Secretary of Global Relations for the American Academy of Ophthalmology (AAO) and in this role she acts as AAO’s ambassador to super national societies such as the European Society of Ophthalmology, the Pan-American Society of Ophthalmology and the Asia-Pacific Society of Ophthalmology. Dr. Fountain previously served as a member of the board of directors of AAO from January 2020 to January 2023 and as AAO’s President in 2021. Dr. Fountain has served as a member of the board of directors of the American Board of Ophthalmology since January 2022 and has also served as an Associate Editor of Ophthalmology, the Journal of the American Academy of Ophthalmology since 2023. She has been on faculty at Rush

University Medical Center in Chicago since May 1998 where she is professor of ophthalmology and section chair emeritus of ophthalmic plastic and reconstructive surgery. She has maintained a private practice, Ophthalmology Partners, Ltd., on Chicago’s North Shore since December 2000. Dr. Fountain was appointed as President of the Harvard Medical Alumni Association in 2026, and will serve a 2-year term after serving as chair for Alumni Fund Giving at Harvard Medical School from January 2016 to June 2019. She served as President of the American Society of Ophthalmic Plastic and Reconstructive Surgery in 2018 and as a member of its board of directors from January 2016 to January 2020. She also served 15 years on the board of directors of Ophthalmic Mutual Insurance Company (“OMIC”) and was elected chair of its board of directors and chair of its audit committee, serving January 2014 to December 2015. Dr. Fountain was President of the Illinois Society of Eye Physicians and Surgeons from January 2002 to December 2005. Dr. Fountain received a B.A. in Human Biology from Stanford University, an M.D. from Harvard Medical School, and in 1992, completed her residency in ophthalmology at Johns Hopkins Hospital’s Wilmer Eye Institute.

We believe that Dr. Fountain’s ophthalmic medical experience and multiple leadership roles in the ophthalmology field qualify her to serve on our Board.

Donald Zurbay has served as a member of our Board since July 2020. Between October 2022 and April 2025, Mr. Zurbay served as the President, Chief Executive Officer and a member of the board of directors of Patterson Companies, Inc. (Nasdaq: PDCO), a publicly traded global medical device company that was acquired by Patient Square Capital. From June 2018 to October 2022, Mr. Zurbay served as the Chief Financial Officer of Patterson Companies. From March 2004 to February 2017, Mr. Zurbay held various leadership positions at St. Jude Medical, Inc., where he most recently served as Vice President and Chief Financial Officer from August 2012 to January 2017. Mr. Zurbay currently serves as a member of the board and member of the audit committee and compliance committee of LivaNova, PLC (Nasdaq: LIVN) and as a member of the board and a member of the audit and finance committee of DENTSPLY SIRONA, Inc. (Nasdaq: XRAY). Mr. Zurbay previously served as a member of the board and member of the audit committee of Avedro, Inc., a formerly publicly traded medical technology company that was acquired by Glaukos Corporation, from July 2017 to 2019, and as a member of the board and chairman of the audit committee of Silk Road Medical, Inc., a formerly publicly traded medical device company that was acquired by Boston Scientific Corporation, from March 2018 to September 2024. Mr. Zurbay is a member of the American Institute of Certified Accountants and the Minnesota Society of Certified Public Accountants. Mr. Zurbay holds a B.S. in Business Accounting from the University of Minnesota.

We believe Mr. Zurbay’s experience with publicly traded healthcare companies and financial expertise qualify him to serve on our Board. As a member of our Board, Mr. Zurbay has effectively employed his deep accounting background in combination with his senior executive experience and extensive medical device industry background to effectively help guide the strategic direction of the Company.

Our Audit Committee has appointed Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. Our Board has directed that this appointment be submitted to our stockholders for ratification at the Annual Meeting. Although ratification of our appointment of Deloitte & Touche LLP is not required, we value the opinions of our stockholders and believe that stockholder ratification of our appointment is a good corporate governance practice. Deloitte & Touche LLP has served as our independent registered public accounting firm since 2019.

Neither Deloitte & Touche LLP nor any of its members has any direct or indirect financial interest in or any connection with us in any capacity other than as our auditors, providing audit and non-audit services. A representative of Deloitte & Touche LLP is expected to attend the Annual Meeting and have an opportunity to make a statement and be available to respond to appropriate questions from stockholders.

In the event the appointment of Deloitte & Touche LLP is not ratified by the stockholders, the Audit Committee will consider this fact when it appoints the independent auditors for the fiscal year ending December 31, 2027. Even if the appointment of Deloitte & Touche LLP is ratified, the Audit Committee retains the discretion to appoint a different independent auditor at any time if it determines that such a change is in the best interest of the Company and its stockholders.

This proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively (excluding abstentions) at the Annual Meeting by the holders entitled to vote thereon. Abstentions are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal. Because a bank or brokerage firm may generally vote without instructions on this proposal, we do not expect any broker non-votes on this proposal.

The Audit Committee has reviewed the audited consolidated financial statements of Sight Sciences, Inc., a Delaware corporation (the “Company”), for the fiscal year ended December 31, 2025 and discussed these financial statements with management and the Company’s independent registered public accounting firm. The Audit Committee has also received from, and discussed with, the Company’s independent registered public accounting firm various communications that such independent registered public accounting firm is required to provide to the Audit Committee, including the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (“PCAOB”) and the Securities and Exchange Commission.

The Company’s independent registered public accounting firm also provided the Audit Committee with a formal written statement required by PCAOB Rule 3526 (Communications with Audit Committees Concerning Independence) describing all relationships between the independent registered public accounting firm and the Company, including the disclosures required by the applicable requirements of the PCAOB regarding the independent registered public accounting firm’s communications with the Audit Committee concerning independence. In addition, the Audit Committee discussed with the independent registered public accounting firm its independence from the Company.

Based on its discussions with management and the independent registered public accounting firm, and its review of the representations and information provided by management and the independent registered public accounting firm, the Audit Committee recommended to the Board of Directors that the audited consolidated financial statements be included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

This Audit Committee Report shall not be deemed incorporated by reference by any general statement incorporating by reference this Proxy Statement into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Securities Exchange Act of 1934, as amended (the “Exchange Act”), except to the extent that the Company specifically incorporates this information by reference, and shall not otherwise be deemed filed under the Securities Act or the Exchange Act.

The following table summarizes the fees of Deloitte & Touche LLP, our independent registered public accounting firm, billed to us for each of the last two fiscal years for audit and other services:

Audit fees for the fiscal years ended December 31, 2025 and 2024 include fees associated with the audit of our consolidated balance sheets, our related consolidated statements of operations and comprehensive loss, and our consolidated statements of stockholders’ equity and cash flows, the assessment of our internal control over financial reporting, the review of the unaudited interim quarterly financial statements included in our Quarterly Reports on Form 10-Q, and other professional services provided in connection with statutory and regulatory filings or engagements and services. For the fiscal year ended December 31, 2024, fees included $44,500 associated with procedures performed by Deloitte & Touche LLP with respect to the Company’s debt refinancing.

Audit-related fees include fees for assurance and related services by Deloitte & Touche LLP that are reasonably related to the performance of the audit or review of our financial statements. There were no audit-related fees for the fiscal years ended December 31, 2025 and 2024.

Tax fees include fees incurred for tax services, including tax compliance, tax advice and tax planning matters. Tax services for the fiscal year ended December 31, 2024 were for services associated with a research and development tax credit analysis. There were no tax fees for the fiscal year ended December 31, 2025.

All Other Fees for the fiscal year ended December 31, 2025 includes subscription fees for the Deloitte Accounting Research Tool.

The Audit Committee has adopted a policy (the “Pre-Approval Policy”) that sets forth the procedures and conditions pursuant to which audit and non-audit services proposed to be performed by the independent auditor may be pre-approved. The Pre-Approval Policy generally provides that we will not engage Deloitte & Touche LLP to render any audit, audit-related, tax or permissible non-audit service unless the service is either (i) explicitly approved by the Audit Committee (“specific pre-approval”) or (ii) entered into pursuant to the pre-approval policies and procedures described in the Pre-Approval Policy (“general pre-approval”). Unless a type of service to be provided by Deloitte & Touche LLP has received general pre-approval under the Pre-Approval Policy, it requires specific pre-approval by the Audit Committee or by a designated member of the Audit Committee to whom the committee has delegated the authority to grant pre-approvals. Any proposed services exceeding pre-approved cost levels or budgeted amounts will also require specific pre-approval. For both types of pre-approval, the Audit Committee will consider whether such services are consistent with the SEC’s rules on auditor independence. The Audit Committee may, on a periodic basis, review and generally pre-approve the services (and related fee levels or budgeted amounts) that may be provided by Deloitte & Touche LLP without Deloitte & Touche LLP first obtaining specific pre-approval from the Audit Committee. The Audit Committee may revise the list of general pre-approved services from time to time, based on subsequent determinations. The Audit Committee has pre-approved all services performed since the Pre-Approval Policy was adopted.

The following table identifies our current executive officers:

The biographies for Paul Badawi and David Badawi, M.D. are set forth in the section titled “Proposals to be Voted Upon—Proposal 1: Election of Directors.”

Ms. Bauerlein has served as our Chief Operating Officer since November 2025. She previously served as our Chief Financial Officer and Treasurer between April 2023 and November 2025. Ms. Bauerlein co-founded Inogen, Inc. (“Inogen”) (Nasdaq: INGN), a publicly traded medical technology company, in 2001, and previously served as Inogen’s Executive Advisor from December 2021 to April 2022, Chief Financial Officer from 2009 until December 2021, Executive Vice President of Finance from March 2014 until December 2021, Corporate Secretary from 2002 until July 2021, and Corporate Treasurer from 2002 until December 2021. Ms. Bauerlein also serves as a member of the board of directors of Koya Medical, Inc. and Balance Ophthalmics, Inc, two private medical device companies. Ms. Bauerlein previously served as a member of the board of Pear Therapeutics, Inc., a software-based digital therapeutics company, from December 2021 to May 2024, and served as a member of the board of directors of Gelesis Holdings, Inc, a biotherapeutics company, from January 2022 until October 2023 and as a member of the board of directors of Equinox Ophthalmic, Inc. from June 2020 until March 2023. Ms. Bauerlein received a B.A. in Economics/Mathematics with high honors from the University of California, Santa Barbara.

Mr. Rodberg has served as our Chief Financial Officer and Treasurer since November 2025. Mr. Rodberg has over 20 years of public accounting and company finance leadership experience. From May 2021 to November 2025, he served as our Vice President of Finance and Corporate Controller, with a brief term of service as our interim Chief Financial Officer from January to April 2023. Prior to joining us, he served as Vice President, Financial Planning and Analysis at nVent Electric plc (NYSE:NVT), a publicly traded electrical infrastructure company, from December 2018 to May 2021. Prior to nVent, Mr. Rodberg served as Director of Finance at Abbott Laboratories (NYSE: ABT), a publicly-traded healthcare company, and had several finance and accounting roles of increasing responsibility at St. Jude Medical, Inc. prior to its acquisition by Abbott Laboratories. He began his career at Deloitte & Touche, LLP in the audit and assurance practice. Mr. Rodberg received a B.S. in Accounting from the University of Minnesota and is a Certified Public Accountant (inactive).

Mr. Hayden has served as our Chief Legal Officer since April 2020. From August 2017 to April 2020, Mr. Hayden served as General Counsel of Endologix, Inc., a medical device company focused on vascular disease. Prior to that, Mr. Hayden served as General Counsel and Vice President, Business Development at Cytori Therapeutics, Inc., a life sciences company (now Plus Therapeutics, Nasdaq CM: PSTV) from July 2015 to August 2017, and from May 2012 to July 2015, he served as Assistant General Counsel at Volcano Corporation, a publicly traded medical device company that was acquired by Royal Phillips in 2015. Mr. Hayden holds a J.D. from the University of Michigan Law School and an A.B. in Politics from Princeton University.

Mr. Taylor has served as our Executive Vice President of Operations since November 2024. Prior to joining us, he worked at NEXT Energy Technologies, Inc., a photovoltaic technology company, between January 2022 and November 2024, where he served in roles of increasing responsibility as Executive Vice President of Engineering from January 2022 to January 2023, as Chief Operating Officer from January 2023 to July 2023 and as Chief Executive Officer from July 2023 to November 2024. Prior to NEXT Energy Technologies, Mr. Taylor served as Executive Vice President of Engineering of Inogen, Inc., a respiratory products company, of which he was a co-founder, from July 2001 to April 2022. Mr. Taylor has over 20 years of experience in medical technology operations, including product engineering and manufacturing. Mr. Taylor received a B.S. in Microbiology with high honors from the University of California, Santa Barbara.

Our Board has adopted Corporate Governance Guidelines, a Code of Business Conduct and Ethics, and charters for our Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, and Commercial Strategy Committee to assist the Board in the exercise of its responsibilities and to serve as a framework for the effective governance of the Company. You can access our Corporate Governance Guidelines, our Code of Business Conduct and Ethics and our committee charters in the “Corporate Governance” section of our investor relations website located at www.investors.sightsciences.com.

Our Board currently consists of seven members: Paul Badawi, David Badawi, M.D., Gerhard Burbach, Staffan Encrantz, Tamara Fountain, M.D., Catherine Mazzacco and Donald Zurbay.

As set forth in our Restated Certificate of Incorporation, the Board is currently divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our Restated Certificate of Incorporation and Amended and Restated Bylaws provide that the authorized number of directors may be changed only by resolution of the Board. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. Our directors may be removed only for cause by the affirmative vote of the holders of at least two-thirds in voting power of all of the then outstanding shares of voting stock of the Company entitled to vote at an election of directors.

Our Board has determined that, of our current directors and director nominees, Gerhard Burbach, Staffan Encrantz, Tamara Fountain, M.D., Catherine Mazzacco and Donald Zurbay do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is “independent” as that term is defined under the rules of The Nasdaq Stock Market LLC (the “Nasdaq rules”). As required by the Nasdaq rules, our Board has made a subjective determination as to each independent director that no relationships exist that, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, the Board reviewed information provided by the directors and the director nominees with regard to each director’s or nominee’s business and personal activities and relationships as they may relate to us and our management.

Except for Paul Badawi and David Badawi, M.D., who are brothers, there are no family relationships among any of our directors, director nominees or executive officers. There are no arrangements or understandings between or among our executive officers and directors pursuant to which any director or executive officer was or is to be selected as a director or executive officer.

Sight Sciences embraces our Board’s diversity of background, experience, culture, and other characteristics that make the Board unique. Diversity at the top sets the expectation for inclusion throughout the organization. As a result, we are disclosing specific diversity-related metrics, including self-identified gender identity, race, and sexual orientation. Two of the seven board directors self-identified with one or more diversity characteristic.

The following table sets forth certain self-identified diversity information for our Board:

The Equal Employment Opportunity Commission (“EEOC”) defines an “underrepresented minority” as an individual who self-identifies in one or more of the following groups: Black or African American, Hispanic or Latinx, Asian, Native American or Alaska Native, Native Hawaiian or Pacific Islander or Two or More Races or Ethnicities. The EEOC defines a “LGBTQ+” as an individual who self-identifies in one or more of the following groups: lesbian, gay, bisexual, transgender, and queer or questioning in regard to their sexual orientation.

We believe that our Board of Directors should have expertise with respect to, and provide oversight over, a broad array of activities and risks. Our Board continuously reviews and assesses its own performance to identify strengths as well as opportunities to enhance Board productivity and effectiveness. Each of our director’s specific skills and experiences with respect to the enumerated categories are included in the table below. Though a particular category may not be checked with respect to a certain director, that director may still possess some level of skill or experience in that area.

Our independent directors meet in executive session on a regularly scheduled basis. Each executive session of the independent directors is presided over by the Chairperson of our Board.

The Nominating and Corporate Governance Committee is primarily responsible for identifying qualified director candidates for election to the Board and recommending to the Board the nominees for election as directors at any meeting of stockholders and the persons to be elected by the Board to fill any vacancies on the Board. To facilitate the

search process, the Nominating and Corporate Governance Committee may solicit current directors and executive officers of the Company for the names of potentially qualified candidates or ask directors and executive officers to pursue their own business contacts for the names of potentially qualified candidates. The Nominating and Corporate Governance Committee may also consult with outside advisors or retain search firms to assist in the search for qualified candidates or consider director candidates recommended by our stockholders. Once potential candidates are identified, the Nominating and Corporate Governance Committee reviews the backgrounds of those candidates, evaluates candidates’ independence from the Company and management, identifies potential conflicts of interest, and determines if candidates meet the qualifications desired by the Nominating and Corporate Governance Committee for candidates for election as a director. In evaluating the suitability of individual candidates (both new candidates and current Board members), the Nominating and Corporate Governance Committee, in recommending candidates for election, and the Board, in approving such candidates, may take into account many factors, including:

The Board evaluates each individual in the context of the Board as a whole, with the objective of assembling a group that can best perpetuate the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of skills and experience in these various areas.

Stockholders may recommend individuals to the Nominating and Corporate Governance Committee for consideration as potential director candidates by submitting the names of the recommended individuals, together with appropriate biographical information, background materials and all other information required for nomination as set forth in the Amended and Restated Bylaws, to the Nominating and Corporate Governance Committee, c/o Corporate Secretary, Sight Sciences, Inc., 4040 Campbell Ave, Suite 100, Menlo Park, California 94025. It is our policy to consider recommendations for director candidates from stockholders holding no less than 1% of the outstanding shares of our common stock continuously for at least 12 months prior to the date of the submission of the recommendation.

In the event there is a vacancy, and assuming that appropriate biographical and background material has been provided on a timely basis, and that the nomination requirements set forth in the Amended and Restated Bylaws have been complied with, the Nominating and Corporate Governance Committee will evaluate stockholder-recommended candidates by following substantially the same process, and applying the same criteria, as it follows for candidates submitted by others.

The Board believes, as a general principle, that management speaks for the Company. Individual directors may, from time to time, communicate with various constituencies that are involved with the Company, but it is expected that Board members would do this with the knowledge of management and, in most instances, only at the request of management. In cases where stockholders and other interested parties wish to communicate directly with our non-management directors, the Board will give appropriate attention to written communications that are submitted by stockholders and will respond if and as appropriate. Our Corporate Secretary is primarily responsible for monitoring communications from stockholders and for providing copies or summaries to the directors as considered appropriate.

Communications are forwarded to all directors if they relate to important substantive matters and include suggestions or comments that our Corporate Secretary and Chairperson of the Board consider to be important for the directors to know. In general, communications relating to corporate governance and long-term corporate strategy are more likely to be forwarded than communications relating to ordinary business affairs, personal grievances and matters as to which we tend to receive repetitive or duplicative communications. Stockholders who wish to send communications on any topic to the Board should address such communications to the Board in writing: c/o Corporate Secretary, Sight Sciences, Inc., 4040 Campbell Ave, Suite 100, Menlo Park, California 94025.

While our Amended and Restated Bylaws provide the Board with flexibility to combine or separate the positions of Chairperson of the Board and Chief Executive Officer, our Corporate Governance Guidelines currently state that it is the Company’s policy that the positions of Chairperson of the Board and Chief Executive Officer must be held by separate persons, and that the Chairperson of the Board must be independent, as determined in accordance with the Nasdaq rules. Staffan Encrantz, our Chairperson of the Board, is independent, and the majority of our Board is comprised of independent directors. Our Board believes that separation of the positions of Chairperson and Chief Executive Officer reinforces the independence of the Board from management, creates an environment that encourages objective oversight of management’s performance and enhances the effectiveness of the Board as a whole. For these reasons, our Board has concluded that our current leadership structure is appropriate at this time.

Our Board will continue to periodically review our leadership structure and may make such changes in the future as it deems appropriate. If, in the future, we deem it appropriate that the Chairperson of the Board also be a member of management or otherwise not otherwise qualify as independent, we will appoint a Lead Independent Director, whose responsibilities would include, but would not be limited to, presiding over all meetings of the Board at which the Chairperson of the Board is not present, including any executive sessions of the independent directors, approving the Board’s meeting schedules and agendas, and acting as liaison between the independent directors of the Board and the Chief Executive Officer and the Chairperson of the Board.

Risk assessment and oversight are an integral part of our governance and management processes. Our Board encourages management to promote a culture that incorporates risk management into our corporate strategy and day-to-day business operations. Management discusses strategic and operational risks at regular management meetings and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks facing us. Throughout the year, senior management reviews these risks with the Board and Board committees at meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks.

Our Board has delegated to our Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee and Commercial Strategy Committee the responsibility for review and oversight of our risks as set forth in the charters of the respective committees and disclosed in the descriptions of each of the committees below. Our Board focuses on overall risk management strategy, the most significant risks facing us, and implementation of attendant risk mitigation strategies, and receives regular reports from the Board committees, management and its outside advisors

with respect to their respective risk oversight activities. Our Audit Committee is responsible for discussing our policies with respect to financial and accounting-related risk assessment and risk management, including guidelines and policies to govern the process by which our exposure to financial risk is handled, and for overseeing management of our financial risks and potential conflicts of interest. Our Nominating and Corporate Governance Committee manages risks associated with the independence of our Board and potential conflicts of interest and also has risk management responsibility for the Company’s non-financial compliance programs, including our healthcare compliance program, anti-bribery and global trade initiatives, cybersecurity program, artificial intelligence initiatives and environmental, social and governance (“ESG”) program. Our Compensation Committee is responsible for overseeing the management of risks relating to our executive and director compensation plans and arrangements. Our Commercial Strategy Committee is responsible for overseeing our product commercialization strategies and identification and mitigation of attendant risks.

We adopted a Code of Business Conduct and Ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions. We have also adopted Corporate Governance Guidelines that address items such as the qualifications and responsibilities of our directors and director candidates, and corporate governance policies and standards applicable to us in general. You can access a copy of the Code of Business Conduct and Ethics and Corporate Governance Guidelines in the “Corporate Governance” section of our investor relations website located at www.investors.sightsciences.com. In addition, we intend to post on our website all disclosures that are required by law or the Nasdaq rules concerning any amendments to, or waivers from, any provision of the Code of Business Conduct and Ethics.

Our Board has adopted an Insider Trading Compliance Policy, which applies to all of our directors, officers and employees and any entities they control (the “Covered Persons”). Among other things, the policy prohibits the Covered Persons from purchasing financial instruments such as prepaid variable forward contracts, equity swaps, collars, and exchange funds, or otherwise engaging in transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of the Company’s securities, or that may cause an officer, director, or employee to no longer have the same objectives as the Company’s other stockholders.

In addition, the policy prohibits the Covered Persons from effecting margin purchases of the Company’s securities. Purchasing on margin means borrowing from a brokerage firm, bank or other entity in order to purchase the Company’s securities (other than in connection with a cashless exercise of stock options through a broker under the Company’s equity plans). Pledging the Company’s securities as collateral to secure loans is also prohibited, with the exception of (i) pledges made before the Company’s initial public offering or (ii) pledges made with the prior written approval of the compliance officer under the policy.

A copy of the Insider Trading Compliance Policy has been filed as an exhibit to the 2025 Annual Report.

Under our Corporate Governance Guidelines, a director is expected to spend the time and effort necessary to properly discharge his or her responsibilities. Accordingly, a director is expected to regularly prepare for and attend meetings of the Board and all committees on which the director sits, with the understanding that, on occasion, a director may be unable to attend a meeting. We do not maintain a formal policy regarding director attendance at annual meetings of stockholders, although it is expected that, absent compelling circumstances, directors will attend these meetings.

There were five meetings of the Board during the fiscal year ended December 31, 2025. During the fiscal year ended December 31, 2025, each director attended at least 75% of the aggregate of (i) all meetings of the Board during the period in which he or she served as a director, and (ii) all meetings of the committees on which the director served during the period in which he or she served as a committee member. All but one of the members of the Board who served as directors during 2025 attended the 2025 Annual Meeting of Stockholders.

Our Board has established four standing committees — the Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee and Commercial Strategy Committee — each of which operates under a charter that has been approved by our Board.

The current members of each of the Board committees and committee chairpersons are set forth below:

Our Audit Committee oversees our accounting and financial reporting process, as well as the audits of our financial statements. Our Audit Committee’s responsibilities include, among other things:

The Audit Committee charter is available on our investor relations website at http://www.investors.sightsciences.com in the “Corporate Governance” section under “Committee Charters.” The current members of the Audit Committee are Staffan Encrantz, Catherine Mazzacco, and Donald Zurbay. Mr. Zurbay currently serves as the Chairperson of the Audit Committee and is expected to continue serving as such following the Annual Meeting. Our Board has affirmatively determined that each member of the Audit Committee is independent for purposes of serving on an audit committee under applicable SEC and Nasdaq rules.

The members of our Audit Committee meet the requirements for financial literacy under the applicable Nasdaq rules. In addition, our Board has determined that Mr. Zurbay qualifies as an “audit committee financial expert,” as such term is defined in Item 407(d)(5) of Regulation S-K, and meets the requirement under the applicable Nasdaq rules that the Audit Committee have a financially sophisticated member.

The Audit Committee met four times in 2025.

Our Compensation Committee oversees the discharge of the responsibilities of the Board relating to the compensation and benefits of our executive officers and directors. Our Compensation Committee’s responsibilities include, among other things:

The Compensation Committee charter is available on our investor relations website at www.investors.sightsciences.com in the “Corporate Governance” section under “Committee Charters.” The current members of our Compensation Committee are Gerhard Burbach, Tamara Fountain, M.D., and Donald Zurbay. Mr. Burbach currently serves as the Chairperson of the Compensation Committee and is expected to continue serving as such following the Annual Meeting. Our Board has affirmatively determined that each member of the Compensation Committee is independent for purposes of serving on a Compensation Committee under applicable SEC and Nasdaq rules and qualifies as a “non-employee director” as defined in Rule 16b-3 of the Exchange Act.

The Compensation Committee generally considers the Chief Executive Officer’s recommendations when making decisions regarding the compensation of non-employee directors and executive officers (other than the Chief Executive Officer). The Compensation Committee may, in its sole discretion, retain or obtain advice from compensation consultants, legal counsel or other advisors, to assist in carrying out its responsibilities and will consider the factors affecting independence required by applicable SEC and Nasdaq rules, in connection with retaining or obtaining the advice of such consultants, counsel and advisors.

In 2025, as with prior years, the Compensation Committee engaged Compensia, Inc. (“Compensia”) as its independent compensation consultant. Compensia’s material responsibilities include (i) advising the committee on the selection of an appropriate peer group of other publicly traded healthcare companies, (ii) collecting and analyzing compensation data from the peer group companies, (iii) performing an independent review of our compensation practices for our executive officers and non-employee directors as compared to the peer group, (iv) providing advice with respect to the our cash incentive compensation and equity grant practices and strategy, and (v) making recommendations regarding the design and structure of our compensation program. Compensia reports directly to the Compensation Committee and performs services for the Compensation Committee in accordance with the directives and guidance provided by the Compensation Committee. For additional information, please refer to the section titled “Compensation Consultant.”

The Compensation Committee met five times in 2025.

Our Nominating and Corporate Governance Committee recommends to our Board nominees for election as directors and develops and maintains our corporate governance policies. Our Nominating and Corporate Governance Committee’s responsibilities include, among other things:

The Nominating and Corporate Governance Committee charter is available on our investor relations website at www.investors.sightsciences.com in the “Corporate Governance” section under “Committee Charters.” The current members of our Nominating and Corporate Governance Committee are Gerhard Burbach, Staffan Encrantz and Tamara Fountain, M.D. Mr. Encrantz currently serves as the Chairperson of the Nominating and Corporate Governance Committee and is expected to continue serving as such following the Annual Meeting. Our Board has affirmatively determined that each member of the Nominating and Corporate Governance Committee is independent for purposes of serving on a Nominating and Corporate Governance Committee under applicable Nasdaq rules.

The Nominating and Corporate Governance Committee has the authority to consult with outside advisors or retain search firms to assist in the search for qualified candidates, or consider director candidates recommended by our stockholders.

The Nominating and Corporate Governance Committee met four times in 2025.

Our Commercial Strategy Committee provides oversight and advice to management on matters relating to the Company’s product commercialization strategy. Our Commercial Strategy Committee’s responsibilities include, among other things:

The Commercial Strategy Committee charter is available on our investor relations website at www.investors.sightsciences.com in the “Corporate Governance” section under “Committee Charters.” The current members of our Commercial Strategy Committee are Gerhard Burbach, Catherine Mazzacco, and Staffan Encrantz. Ms. Mazzacco currently serves as the Chairperson of the Commercial Strategy Committee and is expected to continue serving as such following the Annual Meeting. Our Board has affirmatively determined that each member of the Commercial Strategy Committee is independent under applicable SEC and Nasdaq rules.

The Commercial Strategy Committee met five times in 2025.

This section discusses the material components of the executive compensation program for our named executive officers. We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as well as a “smaller reporting company” as defined by applicable SEC rules. As such, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies or smaller reporting companies, including reduced executive compensation disclosures. We have relied on certain aspects of these exemptions in preparing the disclosure in this section.

This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs and future effects of current compensation programs. Actual compensation programs that we adopt in the future may differ materially from the existing programs summarized in this discussion. For additional information regarding these risks and uncertainties, please refer to the section titled “Cautionary Note Regarding Forward-Looking Statements.”

Our mission is to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – allowing people to keep seeing. We are passionate about improving patients’ lives by helping them to preserve their sight. Our business philosophy is grounded in the following principles: comprehensively understanding disease physiology; developing transformative technologies that are intended to preserve, protect, and restore natural physiological functionality to diseased eyes; developing and marketing products with proven clinical evidence that achieve superior effectiveness versus current treatment paradigms while minimizing complications or side effects; providing intuitive, patient friendly, interventional solutions to ophthalmologists and optometrists (together, “ECPs”); and delivering compelling economic value to all stakeholders, including patients, providers and third-party payors such as Medicare and commercial insurers. Our objective is to develop and market products for use in new treatment paradigms and to create an interventional mindset in eyecare whereby our technologies may be used in procedures which supplant conventional outdated approaches.

We currently offer two commercial technologies in our Interventional Glaucoma business segment, our OMNI® Surgical System (“OMNI”) and our SION® Surgical Instrument (“SION”), both of which enable minimally invasive glaucoma surgery (“MIGS”) procedures. We sell OMNI and SION to facilities where ophthalmic surgeons perform outpatient procedures, such as ambulatory surgery centers and hospital outpatient departments, which are typically reimbursed by Medicare or private payors for procedures using our products. We are focused on educating surgeons on the clinical benefits of earlier interventions with the comprehensive OMNI procedure, enhanced competitive counter selling, investments in targeted commercial resources, a next-generation OMNI product launch, and continued development of the OMNI “standalone” market (“Standalone Market”), which is the market for OMNI procedures that are performed on primary open angle glaucoma (“POAG”) patients without concomitant cataract surgery (“Standalone Procedures”).

In our Interventional Dry Eye business segment, we offer one commercial technology, our TearCare® system (“TearCare”). The TearCare system is a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production. Our goals with the development of TearCare are to fully transform the current outdated treatment paradigm based primarily on over-the-counter and prescription eyedrops, and establish use of TearCare as the standard of care for the millions of patients suffering from evaporative dry eye disease caused by meibomian gland disease. Our commercial strategy for TearCare has been to drive awareness and adoption of the TearCare procedure by ECPs while simultaneously expanding equitable coverage and reimbursement through the generation of compelling clinical data and conduct of a targeted coding, coverage and reimbursement initiative.

For 2025, our named executive officers and their positions were:

The primary objective of our executive compensation program is to attract and retain talented executives with the skills necessary to lead us and create long-term value for our stockholders. We recognize there is significant competition for talented executives, especially in the medical device industry, and it can be particularly difficult for early-stage public companies to recruit experienced executives. We have also experienced challenges with our revenue growth, stock price and market capitalization, which have exacerbated these difficulties.

Our executive compensation program is overseen by our Compensation Committee, which we refer to as the “committee” for purposes of this “Executive Compensation” section. The committee is primarily responsible for developing, reviewing and approving our compensation programs, including the compensation arrangements that apply to our named executive officers, and regularly reporting to our Board regarding the adoption and conduct of such programs. In particular, the committee is responsible for overseeing our cash and equity incentive plans, including approving individual grants or awards thereunder. The committee is also responsible for approving corporate performance objectives that are relevant to the compensation of our executive officers and determining our level of achievement relative to those objectives. The cash bonus program for our executive officers is based solely upon achievement of our annual corporate objectives that are reviewed by the committee and approved by our Board; there is no individual goal component tied to our executive officers’ cash bonuses.

In establishing and overseeing our executive compensation program, the committee evaluates the total compensation paid to our named executive officers and other executives relative to available compensation information from companies in our industry that the committee deems suitably similar to us with reference to specific selection criteria, including revenue, market capitalization, industry, stage of growth, and similar considerations. With reference to relevant compensation survey data, the committee has historically benchmarked our executive compensation at the 50^th percentile of peer group for base salary levels and target bonus levels. With respect to equity benchmarking, while our compensation philosophy historically contemplated equity grants at up to the 75^th percentile of peer group, in practice the committee has generally granted equity to our executives in the range of 50^th percentile of peer group, or less in instances where dilution concerns and other factors have led the committee to reduce grant amounts. In the third quarter of 2025, the committee adopted an updated compensation philosophy that does not benchmark any compensation element to a specific percentile; rather, the committee sets executive compensation at levels it deems appropriate after considering all relevant factors, including compensation data and metrics provided by the committee’s independent compensation consultant with respect to similarly-situated executives of our compensation peer group, the nature and impact of our named executive officers’ contributions, our short-term and long-term objectives, dilutive impact of our equity grant practices and overall equity plan share reserve, prevailing market conditions and similar factors.

The committee is also guided by a pay-for-performance philosophy and seeks to design our executive compensation program in a manner that reflects alignment between the compensation opportunity provided to our executive officers and the achievement of our business and strategic objectives. Specifically, our cash incentive program is intended to reward the achievement of measurable, long-term value drivers deemed by the committee to be critical to the success of our business, while providing the potential for payouts above target levels for achievement above expectations, and partial or no pay-outs for failure to achieve objectives. Further, a portion of the 2026 annual equity awards issued to our Chief Executive Officer, Chief Operating Officer and Chief Financial Officer consists of performance-based restricted stock units (“PRSUs”), which will only vest upon achievement of certain revenue performance milestones pre-approved by the committee. We believe the strong correlation between performance-based criteria and the compensation paid under our executive compensation program aligns the interests of our executives with our stockholders and drives a highly accountable culture.

The committee has not established any formal policies or guidelines for allocating between long-term and currently paid compensation, or between cash and non-cash compensation. In determining the amount and mix of compensation elements, and whether each element provides the correct incentives in light of our compensation objectives, the committee relies on its judgment and experience, as well as input from its independent compensation consultant, rather than adopting a formulaic approach to compensation decisions.

During 2023 and 2024, we faced considerable uncertainty regarding Medicare reimbursement for procedures in which our OMNI technology is used. Local coverage determinations (“LCDs”) published by five of the seven Medicare Administrative Contractors (“MACs”) in mid-2023 identified certain non-implantable MIGS procedures as investigational and not reasonable and necessary in the jurisdictions where these MACs administer Medicare Part B benefits, including adult canaloplasty in combination with trabeculotomy (ab interno), a procedure performed with OMNI and for which it is indicated. These prior LCDs (“Prior LCDs”) were withdrawn in late December 2023 before becoming effective and were replaced with updated LCDs (“Final LCDs”) that became effective in November 2024.

The Final LCDs allow for continued coverage of canaloplasty and goniotomy procedures performed with our OMNI and SION technologies in these five MAC jurisdictions. However, each of the Final LCDs adopted a non-coverage policy when an aqueous shunt or stent procedure is performed with another MIGS procedure, such as canaloplasty or goniotomy, at the same time in the same patient (the “Multiple MIGS Exclusion”). As a result of this Multiple MIGS Exclusion, the aggregate number of MIGS devices used in 2025 decreased as compared to 2024. This decrease adversely affected us and other MIGS companies, and further increased competitive pressures and adversely affected our revenues.

The cumulative effect of these LCDs led to significant uncertainty within our industry commencing in mid-2023 and continuing throughout 2024 and into 2025, and this uncertainly was exacerbated by the coverage and payment limitations resulting from the Multiple MIGS Exclusion contained in the Final LCDs.

Thus, in establishing our 2025 compensation program, the committee recognized the importance of addressing and moving past the market disruption and stakeholder concerns caused by the LCDs. It designed the program to align our executives’ compensation opportunities to achievement of what the committee believed were critical 2025 value creation metrics, including a return to revenue growth in both of our business segments, achievement with one or more large payors of equitable reimbursed access to our TearCare procedure, continued financial discipline, enhancement of the features and capabilities of our commercial product portfolio, progression of our product pipeline, and expansion of our library of clinical evidence.

As we progressed further into 2025, it became apparent that the Multiple MIGS Exclusion was causing a greater than anticipated reduction in the number of devices used in MIGS procedures, which adversely affected our Interventional Glaucoma revenues. Further, though we continued to see traction with our efforts to establish and grow the Standalone Market for OMNI, this traction was not sufficient to materially bolster revenue growth in 2025. These headwinds, combined with other factors such as increasing competition, and delayed launch of one of our next generation OMNI products, served to impact achievement of our 2025 revenue goals.

With respect to our Interventional Dry Eye business segment, we increased our efforts in 2025 to receive equitable reimbursement for our TearCare product offering. Our commercial strategy for TearCare has been to drive awareness and adoption of the TearCare procedure by ECPs while simultaneously seeking to lay the foundation for equitable coverage and reimbursement through the generation of compelling clinical data and conduct of a targeted coding, coverage and reimbursement initiative. The committee designed our 2025 cash compensation program to prioritize these relaunch activities with the goal of driving sustainable, equitable payor coverage and payment determinations for the TearCare procedure. However, as we progressed further into 2025, the original expectations around timing for these coverage and reimbursement decisions was not achieved, causing a reduction in both revenue versus expectations and covered lives versus expectations, which impacted 2025 incentive plan payouts.

In the first quarter of 2025, the committee applied its then-current compensation philosophy to the determination of executive compensation, with the recognition that departing from its benchmarking targets was appropriate in various circumstances as deemed advisable to address unanticipated market dynamics, shifting strategic priorities, equity burn rate considerations, outstanding executive performance, or other relevant considerations.

In setting 2025 corporate objectives, the committee recognized that the Final LCDs preserved Medicare coverage and payment for OMNI procedures in the relevant MAC jurisdictions. However, it also recognized that the Final LCDs adversely impacted the MIGS market as a result of the Multiple MIGS Exclusion. Performance of multiple MIGS

procedures at the time of cataract surgery had become an increasingly common practice prior to effectiveness of the Multiple MIGS Exclusion, and this exclusion from coverage was expected to decrease the overall volume of MIGS devices used during the fourth quarter of 2024 and beyond. Taking into account these anticipated market dynamics, the committee recommended 2025 corporate objectives that:

In approving 2025 executive compensation, the committee determined that the enhanced cash bonus targets that had been adopted in 2024 to respond to the significant uncertainty facing our business and to help drive the achievement of critical near-term objectives, were no longer needed. As a result, the 2025 cash incentive program included a significant reduction in the cash bonus targets for the named executive officers relative to the 2024 targets.

Also, in approving 2025 annual equity grants to our named executive officers, the committee continued to adhere to its stated goal of limiting equity grants to an aggregate burn rate equal to approximately six percent (6.0%) of our outstanding shares, despite continued downward pressure on our stock price, which significantly limited the dollar value of such grants. The committee believed it was important to adhere to its voluntarily adopted burn rate target to limit the dilutive impact of our compensation program on stockholders. As a result, our named executive officers received 2025 annual grants that represented only approximately 60% of the total grant value they otherwise would have received had this burn rate cap not been in place. With respect to our Chief Executive Officer, in particular, the value of the annual grant he received was below the 25^th percentile of our peer group.

In the first quarter of 2026, the committee applied its updated compensation philosophy to determination of 2026 executive compensation. The committee engaged in a review of the relevant company market data compiled by our independent compensation consultant per category of compensation and in the aggregate, without targeting specific base salary, cash bonus and equity compensation percentiles. The committee recognized that certain of our executives could be compensated below median of peer group in one or more respects but at or above median in other respects, and that these variances could be appropriate and beneficial in aligning executive performance with creation of long-term value for our stakeholders. Further, as in prior years, 100% of the executive team’s cash bonuses for 2026 were determined based upon achievement of the Board-approved company-wide 2026 corporate goals and objectives. The committee believes that this continued linkage between corporate goals and senior executive cash bonus pay-outs best aligns executive performance with long-term value creation.

In setting our 2026 corporate goals, the committee acknowledged that efforts to drive awareness and adoption of our OMNI system for use in Standalone Procedures continued to present a significant opportunity, but one that is early in its realization, and most of the Interventional Glaucoma revenue growth in 2026 is expected to come from increased combination cataract procedures. Separately, the committee recognized that the establishment by FCSO and Novitas of fee schedules for CPT code 0563T had created significant opportunities not only to drive awareness and sales of the TearCare System in those jurisdictions, but also to leverage these initial fee schedules to educate other payors on the clinical need for, and benefits of, the TearCare procedure. The committee also recognized that importance of continued operating discipline to preserve cash usage for priority initiatives, including the TearCare commercial infrastructure investment, interventional glaucoma Standalone Market development, and product pipeline development. Taking into account these anticipated market and operating dynamics, the committee recommended, and the Board approved, 2026 corporate objectives that:

Also, in approving 2026 annual equity grants to our named executive officers, the committee for the first time approved the grant of PRSUs to our Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. We anticipate that PRSUs will continue to be part of the executive equity grant process going forward. See “Equity Incentive Compensation” below for further discussions of these PRSU grants. Lastly, the committee continued its practice of limiting equity grants to an aggregate burn rate equal to or less than six percent (6.0%) of our outstanding shares. The dilutive impact of our 2026 annual grants, in combination with our projected equity grants for 2026, is expected to be below this 6.0% threshold. The committee believes it was important to adhere to its voluntarily adopted burn rate target where appropriate to limit the dilutive impact of our compensation program on stockholders.

Since the completion of our initial public offering, the committee has engaged Compensia to provide independent compensation advisory services directly to the committee. These services have included: (i) advising the committee on the selection of an appropriate peer group of other publicly traded healthcare companies, (ii) collecting and analyzing compensation data from the peer group companies, (iii) performing an independent review of our compensation practices for our executive officers and non-employee directors as compared to the peer group, (iv) providing advice with respect to the our cash incentive compensation and equity grant practices and strategy, and (v) making recommendations regarding the design and structure of our compensation program.

The decision to engage Compensia was made by the committee, and Compensia reports directly to the committee. While members of our management regularly communicate with representatives of Compensia, our management does not direct or oversee the scope of services provided by or the compensation paid to Compensia.

While we are not obligated to retain an independent compensation consultant, the committee believes the use of an independent consultant provides additional assurance that our compensation program is attractive and competitive in the marketplace, consistent with market conditions, and reflective of our executive compensation philosophy and objectives.

The committee assesses, on at least an annual basis, whether the work of Compensia as a compensation consultant has raised any potential conflicts of interest, taking into account the following factors: (i) the amount of fees paid by us to Compensia as a percentage of that firm’s total revenue, (ii) the provision of other services to us by Compensia, (iii) Compensia’s policies and procedures that are designed to prevent conflicts of interest, (iv) any business or personal relationship of the individual compensation advisors with any member of the committee, (v) any business relationship of Compensia or business or personal relationship of the individual compensation advisors, with any of our executive officers, and (vi) any ownership of our stock by Compensia or the individual compensation advisors. Based on the above factors, the committee has concluded that the work of Compensia, including the work performed by the individual compensation advisors employed by Compensia, has not created any conflict of interest.

In September 2024, the committee considered and approved a peer group, which we refer to as our 2025 peer group, for purposes of assisting the committee in making 2025 compensation decisions. Selecting an appropriate peer is an important aspect of developing our executive compensation program since we have historically benchmarked elements of executive compensation to our peer group as discussed above. Our 2025 peer group was determined primarily based on these companies’ similarities to us as of the time the survey was performed, with reference to factors such as revenue, market capitalization, industry, target markets, stage of growth, number of employees, and primary geographic location. In selecting our 2025 peer group, the committee expressed its desire to generally maintain consistency of our peer group as compared to the previous year, while recognizing that changes in material factors such as market capitalization and revenue may precipitate changes to the group.

Our 2025 peer group was comprised of the 19 following companies in the medical device and biotechnology industries listed below, of which 13 were also part of our 2024 peer group.

In September 2025, the committee considered and approved an updated peer group, which we refer to as our 2026 peer group, which was used for the purpose of assisting the committee in making 2026 compensation decisions. The factors used to select our 2026 peer group were similar to those used in prior years.

Our 2026 peer group is comprised of the 19 companies in the medical device and biotechnology industries listed below, of which 15 were also part of our 2025 peer group.

Our executive compensation program incorporates significant governance practices and policies that we believe support our compensation philosophy and assist us in achieving our compensation objectives. These practices and policies are designed to align our executive compensation program with long-term stockholder interests, reduce compensation-related risk, and reflect governance best practices. The committee evaluates our executive compensation program regularly to ensure it supports our short- and long-term strategic goals given the dynamic nature of our business and the markets in which we compete for executive talent.

Key aspects of our compensation governance practices and policies include:

Our executive compensation program is designed to be competitive and appropriately balance our goals of attracting and retaining our executives and motivating them to achieve strategic objectives. In furtherance of our pay-for-performance philosophy, and to motivate and reward individual initiative and effort, a portion of each executive officer’s target annual compensation opportunity is variable based on our achievement relative to business and strategic objectives. For 2025, the primary elements of our named executive officers’ compensation were base salaries, annual cash incentive compensation, and long-term equity incentive compensation.

The base salaries of our named executive officers are an important part of their total compensation package and are intended to reflect their respective positions, duties and responsibilities. In connection with our annual compensation review in the first quarter of 2025, each of our named executive officers received a base salary increase. For 2025, the base salary amounts for the named executive officers were:

For 2026, Mr. Badawi’s base salary remained unchanged from 2025 ($659,000). The 2026 base salaries for Ms. Bauerlein and Mr. Hayden were adjusted to $500,000 and $450,000, respectively, reflecting standard salary increases commensurate with their performance.

We maintain an annual cash incentive program, or cash bonus program, for all employees who are not eligible for commissions and who are otherwise eligible to participate in the program, including our named executive officers. Participants in the program may earn a performance-based cash bonus based on the achievement of pre-determined business and strategic objectives deemed by the committee to be critical to driving long-term stockholder value. With regard to our senior executives, including our named executive officers, one hundred percent (100%) of their cash bonuses for 2025 were tied to the achievement of pre-determined corporate performance objectives, while the cash bonuses payable to our other employees were determined with regard to the achievement of a combination of corporate and individual performance metrics. The committee believes this approach is appropriate because our senior executives are in the best position to drive the achievement of our corporate objectives and the committee holds our executives directly accountable for the results.

For 2025, the named executive officers had the following target annual bonus amounts, expressed as a percentage of base salary for the year:

Target cash bonus percentages for each named executive officer were determined by the committee based on a review of compensation data from the 2025 peer group provided by Compensia, as well as other compensation data and additional factors deemed relevant by the committee. In particular, the committee, in consultation with our Chief Executive Officer, considered the following factors in determining the 2025 target cash bonus percentages for our executives:

The reduction in the target bonus percentages for Mr. Badawi, Ms. Bauerlein and Mr. Hayden from 90%, 80%, and 80%, respectively, pursuant to the 2024 executive compensation program, to 75%, 60% (subsequently increased to 65%) and 50%, respectively, pursuant to the 2025 executive compensation program, reflected a return to a comparatively more stable operating environment and competitive incentive compensation levels with our peers. For additional information, please refer to the section titled “Application of Compensation Philosophy to 2025 Executive Compensation.”

For 2026, Mr. Badawi’s target cash bonus percentage increased from 75% to 90%, and Ms. Bauerlein’s and Mr. Hayden’s target cash bonus percentages remained unchanged from the prior year at 65% and 50%, respectively. These target cash bonus percentages were determined by the committee based on a review of compensation data from the 2026 peer group provided by Compensia, as well as other compensation data and additional factors deemed relevant by the committee. In particular, the increase in Mr. Badawi’s target cash bonus percentage was intended to raise his target cash bonus percentage to approximately the 50^th percentile of our 2026 peer group.

We designed our 2025 cash incentive compensation program to drive performance against and motivate achievement of the following objectives:

In particular, our 2025 cash bonus program incorporated performance-based metrics to ensure compensation paid to our executives was correlated with the achievement of business and strategic objectives deemed by the committee to be critical to driving long-term stockholder value.

The business and strategic objectives approved by the committee for the 2025 cash bonus program related to pre-determined revenue (weighted 40%), adjusted operating expense (weighted 20%), market access (weighted 20%), clinical/research and development (weighted 10%) and commercial product launch (weighted 10%) objectives. For each of the objectives, the committee adopted minimum threshold targets such that no payments were eligible to be made with respect to these objectives if the minimum performance level was not achieved. The committee also adopted maximum payouts for each of the components regardless of the performance levels for each component to ensure aggregate bonus payments are reasonable, commensurate with the strategic value of the achievement of such components, and limit compensation-related risk.

The committee also approved two additional objectives, or “kickers,” to reward achievement of other strategic initiatives deemed important and accretive if achieved in 2025, which added 15% to the cash bonus payout opportunity. Additional information regarding the performance objectives and our performance relative to each objective is provided in the table below.

Revenue (40% of Total Corporate Payout at Target): Revenue was $77.4 million for 2025, a decrease of 3% compared to $79.9 million in 2024, with Interventional Glaucoma revenue slightly down by $0.2 million or 0% versus prior year, and Interventional Dry Eye revenue decreasing by $2.3 million, or 59% versus the prior year. Target revenue for 2025 was $91.0 million, which assumed revenue growth in both business segments. This $77.4 million revenue total was below the minimum revenue threshold ($82.0 million) necessary to receive any payout for this corporate objective. While we had planned for higher revenue growth in 2025, this growth was lower than expected due to a number of factors including: (i) the impact of the Multiple MIGS Exclusions and other market factors; and (ii) delays in receiving the first equitably priced third-party payor fee schedules for the TearCare procedure as compared to our projections when the 2025 corporate objectives were established and approved.

Adjusted Operating Expenses (20% of Total Corporate Payout at Target): We received the maximum payout (at 150% of target) for our achievement of this corporate objective. Total operating expenses were $103.8 million for 2025, representing a 13% decrease compared to $118.8 million for 2024. Adjusted operating expenses were $87.8 million for 2025, down from $101.3 million for 2024, representing a 13% decrease. Target adjusted operating expenses for 2025 were $115.0 million.

Our reduction in operating expenses and adjusted operating expenses in 2025 reflected an intentional focus on operational discipline and operating expense management throughout the year to minimize cash utilization due to the revenue shortfall versus expectations. We scrutinized expenditures across the organization to reduce or eliminate spend that was not necessary or advisable to support our strategic objectives, while still investing in key areas including TearCare market access, Standalone Market development, and key product pipeline initiatives. This review resulted in our implementation of a targeted restructuring plan to reduce operating expenses, improve cost efficiencies, and better align our operating structure for long-term, profitable growth. This restructuring, which we consummated in the third quarter of 2025, resulted in (i) a reduction in headcount equal to approximately 20% of our global workforce and, (ii) reductions in our selling, general and administrative operating expenses as well as reductions in certain research and development project spend. This restructuring, as well as our continued operating discipline, were instrumental in helping us to materially reduce our operating expenses in 2025 versus 2024 and reach the maximum payout on the adjusted operating expense target.

‘Adjusted’ operating expenses is a financial measure not prepared in accordance with generally accepted accounting principles in the United States (“GAAP”, and therefore such a measure, is a “non-GAAP financial measure”), and is calculated as operating expenses less stock-based compensation expense, depreciation and amortization, restructuring costs, and other one-time or non-recurring costs. We believe this non-GAAP financial measure is an important performance indicator because it excludes items that are unrelated to, and may not be indicative of, our core financial and operating results.

Market Access Objectives (20% of Total Corporate Payout at Target): Our multi-pronged 2025 Interventional Dry Eye market access strategy included concerted outreach and engagement with commercial payors and MACs and the continued generation of compelling clinical and health economics data. Regarding our market access objectives:

Though the establishment of equitable fee schedules by FCSO and Novitas resulted only in partial achievement of our covered lives objective, it provided concrete and material validation of the clinical efficacy of, and medical need for, the TearCare procedure, as payors have increasingly recognized the significance of our SAHARA clinical trial results and the compelling health economics associated with the TearCare procedure as compared to prescription eyedrops (the current standard of care). Achievement of our market access objectives pertaining to average payment rates for CPT code 0563T provided further evidence of TearCare’s commercial value and its addressable market opportunity. Satisfaction of our TearCare market access objectives was a critical step in our efforts to obtain and maintain broad, equitable coverage and payment for our TearCare procedure from third party payors.

Clinical and R&D Objectives (10% of Total Corporate Payout at Target): We achieved at target (100% of target) and above target (125% of target) on our two clinical/research and development objectives, resulting in (i) an important expansion of our TearCare clinical evidence portfolio as we continue to engage with payors to drive broader coverage and equitable payment for the TearCare procedure; and (ii) completion of the next step in the development of our canalicular scaffolding technology, which technology is a key part of our product pipeline. We continue to engage in disciplined investment in our clinical evidence portfolio and product pipeline as these activities are core to fulfilling our mission. These initiatives demonstrate the commitment of our dedicated management team and employees to developing and bringing needed best-in-class interventional solutions to the market.

Commercial Objective (10% of Total Corporate Payout at Target): We did not achieve our 2025 commercial objective (0% of target), which was the commercial launch of a next generation OMNI product. We did achieve the launch of another next-generation OMNI product, OMNI Edge; however our 2025 commercial objective was specific to another launch and thus the objective was not achieved.

Additional Objectives (Kickers): We did not achieve either of our additional 2025 high-value corporate objective incentives, or “kickers,” though we made substantial progress with respect to both. These kickers represented a potential 15% enhancement to our target bonus opportunity. The first “kicker,” which represented a 10% potential enhancement to our target bonus opportunity, required establishment in 2025 of a minimum number of coverage policies with commercial payors and/or appropriate fee schedules with MACs or other large commercial payors. Though we did not achieve this minimum threshold, we received important validation of the commercial and clinical value of the TearCare procedure when FCSO and Novitas established fee schedules in October 2025 for CPT code 0563T, the code specifically associated with our TearCare procedure.

The second “kicker,” which represented a 5% enhancement to our target bonus opportunity, required initiation of a proof-of-principle clinical trial in 2025 with respect to one of our primary pipeline products. We did not achieve this kicker but we continue to dedicate resources to development of this pipeline product.

The following table sets forth the 2025 business and strategic objectives, the relative weighting of each objective, the 2025 target for each objective, a brief summary of the actual 2025 performance relative to each objective, and the resulting achievement percentage for each objective.

In January 2026, the committee determined the level of achievement relative to our 2025 corporate and strategic objectives, as described above, was 67.7% of the target cash bonus opportunity, resulting in the payment of bonuses to our named executive officers in an amount equal to that same percentage of their respective target cash bonus amounts. The cash bonus payout percentage reflected the achievement of business and strategic objectives that are critical to driving long-term stockholder value. While the 2024 cash bonus payout exceeded the target amounts, the average cash bonus payout for 2023, 2024 and 2025 is equal to approximately 78% of target, reflecting the committee’s commitment to fiscal discipline and a pay-for-performance philosophy.

The 2025 cash bonuses paid to our named executive officers are included in the “Non-Equity Incentive Plan Compensation” column of the 2025 Summary Compensation Table below.

We generally offer equity awards as the long-term incentive component of our executive compensation program. New equity awards are made pursuant to our 2021 Incentive Award Plan, which has been approved by our Board and stockholders.

Historically, we offered stock options to our employees, but beginning in September 2021, we commenced the grant of restricted stock units, or RSUs, in addition to stock options. Stock options generally allow employees to purchase shares of our common stock at a price equal to the fair market value of our common stock on the grant date, as determined by the Board. RSUs generally allow employees to receive shares of our common stock upon the vesting and settlement of the RSUs.

Stock options granted upon an employee’s commencement of employment generally vested as to 25% of the underlying shares on the first anniversary of the grant date and in equal monthly installments over the following three years. Subsequent grants of stock options to employees generally vested as to 1/48^th of the shares underlying the stock option each month for four years following the grant date. Historically, our stock options have been intended to qualify as “incentive stock options” to the extent permitted under the Internal Revenue Code. The committee did not grant any stock options during 2025.

Prior to 2024, the RSUs we granted generally vested in four equal annual tranches on each anniversary of the grant date. Commencing with our 2024 annual equity grant cycle, we have granted RSUs in our annual equity grant cycle that vest in equal quarterly installments over four years following the grant date. In the case of new executive employees, RSUs typically vest as to 25% of the underlying shares on each anniversary of the grant date over four years following the grant date. In the case of new non-executive employees, RSUs vest as to 25% of the underlying shares on the first anniversary of the grant date and then in equal quarterly installments over the following three years.

Pursuant to our current equity grant philosophy:

During 2025, the committee continued to assess the vesting metrics applicable to future grants of equity awards. We have historically issued equity awards subject only to time-based vesting, but the committee has periodically evaluated the appropriate timing for the potential introduction of performance-based equity awards for executives. The committee engaged in further discussions regarding the structure of any performance-based equity awards, including the type of equity award (RSUs or stock options or a combination of both), appropriate vesting metrics for the equity awards (performance-based, or a combination of performance-based and time-based), and the proposed recipients of any performance-based equity awards. Following thorough analysis, the committee affirmed its intention to introduce performance-based vesting for equity awards granted to our key executives as part of our executive compensation program, and decided to do so as part of the 2026 equity grant cycle (see “2026 Executive Equity Grants” below).

For the 2025 equity grant cycle, the committee determined that, in light of (i) our market capitalization and current stage of growth, (ii) the continuing uncertainties in 2025 regarding revenue growth expectations in both interventional glaucoma and interventional dry eye segments due to market factors, (iii) the difficulty in identifying performance-based metrics that would align the vesting of equity awards with the achievement of objectives that increase stockholder value, while also providing meaningful retentive value for our executives, and (iv) the committee’s determination to limit the burn rate under our equity plan (which resulted in the issuance of annual grants to our named executive officers that represented only approximately 60% of the total grant value they otherwise would have received), it was too early in our life cycle to grant performance-based equity awards that would ensure appropriate alignment between executive

performance and the achievement of long-term stockholder value. Accordingly, the committee determined that awards issued as part of the 2025 equity grant cycle would continue to be subject only to time-based vesting. Taking into account the factors discussed above, the committee granted RSU awards to our named executive officers in 2025 as described in the table below:

In its review of 2026 executive compensation, the committee assessed our financial performance, critical success metrics, peer company practices, the types of performance-based metrics that would effectively align executive incentives with company performance, and related considerations.

In the first quarter of 2026, as part of the annual equity grant cycle, the committee approved the grant of RSUs and PRSUs to Mr. Badawi, our Chief Executive Officer, Ms. Bauerlein, our Chief Operating Officer, and James Rodberg, our Chief Financial Officer. Pursuant to these grants, 50% of Mr. Badawi’s total 2026 annual equity grant and 25% of Ms. Bauerlein’s and Mr. Rodberg’s 2026 annual equity grants (by dollar value) were comprised of PRSUs. The remainder of their equity awards were RSUs subject to time-based vesting in accordance with our standard vesting schedule. The PRSUs will vest based on achievement of certain levels of 2026 revenue performance: none of the PRSUs will vest if our 2026 revenues fail to achieve a certain minimum threshold, 100% of the PRSUs will vest if our 2026 revenues hit the target threshold (the “Target PRSUs”), and a maximum of 200% of the target PRSUs will vest if our 2026 revenues equal or exceed the maximum threshold (with linear interpolation between thresholds). Any PRSUs that are actually earned after determination of revenue achievement in 2026 will vest over three years in equal, consecutive annual installments with the first installment vesting upon the date of final determination of 2026 revenue achievement and corresponding award of earned PRSUs. The committee believes that performance-based equity awards will play an important role in our equity compensation structure moving forward as our business evolves and we gain more insight into longer-term market opportunities for our products.

The committee granted RSU awards to our named executive officers in 2026 as described in the table below:

Our named executive officers are eligible to participate in our employee benefit plans and programs, including medical, dental, and vision benefits and long-term disability insurance, basic life insurance, and health savings accounts, to the same extent as our other full-time employees, subject to the terms and eligibility requirements of those plans. We also sponsor a 401(k) defined contribution plan in which our named executive officers may participate, subject to limits imposed by the Code, to the same extent as our other full-time employees. We made employer contributions to the 401(k) plan for 2025 in an amount equal to 25% of the first 6% of eligible compensation deferred during 2025. We have not typically provided our executive officers with any perquisites, and none of our named executive officers received perquisites in 2025. We design our employee benefits programs to be affordable and competitive in relation to the market, and compliant with applicable laws and practices. We adjust our employee benefits programs as needed based upon changes in applicable laws and market practices.

We entered into employment agreements with each of our named executive officers. Under the employment agreements, if we terminate a named executive officer’s employment without “cause,” or the named executive officer resigns for “good reason” (and other than in connection with a change in control), subject to the execution and non-revocation of a separation agreement and release with the Company and compliance with restrictive covenants contained therein, the named executive officer will be entitled to receive (i) continued payment of base salary for 18 months for Mr. Badawi, or 12 months for Ms. Bauerlein and Mr. Hayden , (ii) any unpaid bonus earned for the year prior to the year of termination, (iii) for Mr. Badawi, a prorated annual bonus for the year of termination based on actual performance and payable when annual bonuses for such year are paid to other executives of the Company, and (iv) direct payment of or reimbursement for COBRA premiums, less the amount the named executive officer would have paid for coverage as an active employee, for up to 18 months for Mr. Badawi, and for up to 12 months for Ms. Bauerlein and Mr. Hayden. If such a qualifying termination occurs on or within 12 months following the date of a change in control, subject to the execution and non-revocation of a separation agreement and release with the Company and compliance with restrictive covenants contained therein, the named executive officer will be entitled to receive, in lieu of the payments and benefits described above, (i) continued payment of the named executive officer’s base salary for 24 months for Mr. Badawi, or 18 months for Ms. Bauerlein and Mr. Hayden, (ii) any unpaid bonus earned for the year prior to the year of termination, (iii) a payment equal to 2 times for Mr. Badawi, or 1.5 times for Ms. Bauerlein and Mr. Hayden, the named executive officer’s target annual bonus for the year of termination, (iv) direct payment of or reimbursement for COBRA premiums, less the amount the named executive officer would have paid for coverage as an active employee, for up to 24 months for Mr. Badawi, or 18 months for Ms. Bauerlein and Mr. Hayden, and (v) for each named executive officer, all unvested equity or equity-based awards that vest solely based on the named executive officer’s continued employment or service with the Company will accelerate and vest in respect of 100% of the shares subject thereto.

In August 2025, we entered into a separation agreement and release with Mr. Link, pursuant to which, and subject to Mr. Link’s continued compliance with restrictive covenants included in his employment agreement, Mr. Link (i) will receive a separation payment in an amount equal to one year of his base salary, payable in regular installments over the 12 month period following the effective date of August 31, 2025, (ii) is entitled to payment or reimbursement for up to one year of COBRA benefits and (iii) received accelerated vesting of 61,675 unvested RSUs. In connection with his departure, Mr. Link’s executive employment agreement was terminated.

We have adopted a Policy for Recovery of Erroneously Awarded Compensation pursuant to which we are required to seek recoupment or reimbursement with respect to incentive-based compensation paid or awarded to our executive officers when the following three factors exist:

Under the policy, the restatement does not need to be the result of misconduct by the executive officers for the recoupment to apply. The recoupment or reimbursement to be sought by us will be equal to the portion of any performance-based compensation paid to or received by such executive officer for or during each of the restated periods that is greater than the amount that would have been paid or received had the financial results been properly reported.

We believe this policy reinforces our pay-for performance philosophy and contributes to a company culture that emphasizes integrity and accountability in financial reporting.

We maintain stock ownership guidelines to further align the interests of our executive officers and directors with those of our stockholders. Each of our executive officers and directors is required to comply with the minimum ownership levels and timing of compliance outlined in the stock ownership guidelines.

The following are the current guideline levels:

If an executive officer or director fails to reach, or falls below, the minimum ownership level set forth in the stock ownership guidelines, he or she may be required to retain 100% of any net shares derived from vested awards issued under our equity incentive plans until his or her minimum ownership level is met or, if necessary, to maintain the minimum ownership level.

The individuals subject to these guidelines will have until the later of the fifth anniversary of the effective date of the guidelines or, if applicable, five years after the date the covered individual is appointed or elected, as applicable, to his or her position to comply with the minimum stock ownership requirement.

Subject to certain limited exceptions contained in our Insider Trading Compliance Policy, all of our employees, including our executive officers, and the members of our Board, are prohibited from (i) directly or indirectly engaging in any transaction involving our securities while aware of material nonpublic information relating to us, (ii) engaging in transactions involving the securities of any other company while aware of material nonpublic information about that company, (iii) disclosing material nonpublic information concerning us or any other company to friends, family members or any other person or entity not authorized to receive such information where such person or entity may benefit by trading on the basis of such information, (iv) engaging in derivative securities transactions, including hedging our common stock, (v) engaging in short sales of our securities, and (vi) pledging our securities as collateral or holding our securities in a margin account, except for pledges approved in advance by the compliance officer under our Insider Trading Compliance Policy.

We follow the FASB ASC Topic 718 in accounting for our stock-based compensation awards. FASB ASC Topic 718 requires us to measure the compensation expense for all stock-based payment awards made to our employees and members of our Board, based on the grant date “fair value” of these awards. This calculation is performed for accounting purposes and reported in the executive compensation tables required by the federal securities laws, even though the recipient of the awards may realize a different value (or no value) from their awards.

The following table sets forth all of the compensation awarded to or earned by or paid to our named executive officers during 2025 and 2024, as applicable. The amounts set forth in the table have been calculated in accordance with the requirements of applicable SEC rules, and do not necessarily reflect the amounts that have actually been paid to, or which may be realized by, our named executive officers.